NLS Pharmaceutics Moves Forward with Major Corporate Changes
NLS Pharmaceutics Ltd., a leading Swiss biopharmaceutical company focused on advancing innovative treatments for central nervous system disorders, has exciting news regarding its corporate structure. The company has announced its plan to execute a 1-for-10 reverse share split of its common shares, accompanied by a name change as it prepares for an anticipated merger with Kadimastem Ltd.
A New Chapter: Reverse Share Split Announcement
The reverse share split is set to adjust the total number of shares outstanding, consolidating ownership in a way that could enhance shareholder value. After the split, the company's common shares will begin trading under the new symbol "NCEL". This strategic move aims to position NLS Pharmaceutics on the Nasdaq Capital Market effectively, reflecting its refined corporate identity as NewcelX Ltd.
Details Surrounding the Merger and Reverse Split
NLS Pharmaceutics made clear that the reverse share split will take effect following approvals and necessary regulatory steps. Shareholders can expect the reverse split to be officially reflected on Nasdaq soon after, with a new CUSIP number assigned for the company's common shares. Importantly, this move also includes a consolidation of preferred shares at the same 1-for-10 ratio, enhancing overall capital efficiency.
Expected Outcomes Post-Split
Following the implementation of the reverse split and the merger, the surrounding capital structure will reflect a total of 5,533,183 common shares outstanding, in addition to a significant number of preferred shares and participation certificates. This reshaped capital structure is expected to bolster the company’s financial position and attract future investment opportunities.
Shareholder Impact and Company Direction
One of the key points of focus for shareholders is that the reverse split will not dilute individual ownership percentages significantly. Everyone holding shares will see their holdings consolidated, but without losing their stake in the company’s future. NLS Pharmaceutics assures that no fractional shares will be issued, and cash adjustments will be made where necessary. This careful approach aims to maintain trust and confidence among current shareholders during this transition.
Future Prospects for NLS Pharmaceutics
As NLS Pharmaceutics aligns itself with Kadimastem, a company recognized for its work in cell therapy for neurodegenerative diseases, the merger is set to create a formidable player in the biopharmaceutical market. Management is optimistic that combining resources and expertise will not only result in innovative therapies but also enhance shareholder value significantly.
Final Thoughts
For investors and stakeholders, the upcoming changes present a transformative opportunity. NLS Pharmaceutics is not only rebranding but also strategically repositioning itself for future growth and expansion through this merger. With the backing of Kadimastem, there is a promising horizon ahead for innovative therapies that could reshape outcomes for patients with critical central nervous system disorders.
Frequently Asked Questions
What is the reverse share split ratio announced by NLS Pharmaceutics?
The announced reverse share split ratio is 1-for-10, meaning that every ten shares will be consolidated into one share.
What will be the new trading symbol for NLS Pharmaceutics following the split?
The new trading symbol will be "NCEL" after the completion of the reverse split and the merger.
How will this reverse split affect shareholders?
Shareholders will see their shares consolidated, but their percentage ownership and voting power will remain largely unchanged, aside from minor adjustments related to fractional shares.
What is the expected impact of the merger with Kadimastem?
The merger aims to strengthen NLS Pharmaceutics' capabilities in developing therapies for central nervous system disorders, potentially leading to innovative solutions for patients.
Who should I contact for more information about the share split?
VStock Transfer, LLC will act as the exchange agent for the reverse split. They can be contacted at (212) 828-8436 for further information.
